- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02157415
Prospective Cohort Study on Tolerability & Safety of Uro-Tainer® Polihexanide 0.02%
Prospective Cohort Study on the Tolerability and Safety of Uro-Tainer® Polihexanide 0.02% in Long-term Indwelling Catheterized Patients.
It is the first clinical study aimed at assessing the safety and tolerability of UT-P as routine rinsing and bacterial decolonization solution device for urinary catheters. The study will be conducted in hospitalized adult patients who had an urethral or suprapubic catheter in place for longer than two consecutive weeks and who are able to provide written consent.
This is an open-label prospective observational cohort study. No comparative control group is planned as no other preventing infection solution is commercially available at this time.
Study Overview
Status
Intervention / Treatment
Detailed Description
The objective of this study is to assess the tolerability and safety of Uro-Tainer® Polihexadine 0.02% intended as routine rinsing and bacterial decolonization of urinary catheters in long-term catheterized patients. After each instillation patients will be assessed for vital signs, skin reactions and other symptoms suggesting intolerance or sensitivity and/or allergic reaction. In addition, pain will be assessed in the first 5 patients and any other patients with sustained pain sensation in the bladder.
Catheters will be rinsed by gravity feed with 100ml solution of UT-P 0.02% once a day for a maximum of 5 instillations. A minimum interval of 24 hours must be guaranteed for the enrolment of the first 5 patients and their first irrigation with the investigational product.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Gent, Belgium, 9000
- Universitair Ziekenhuis
-
-
-
-
-
Beelitz Heilstätten, Germany, 14547
- Kliniken-Beelitz GmbH
-
-
-
-
BS
-
Basel, BS, Switzerland, 4056
- Schweizerisches Paraplegikerzentrum
-
-
LU
-
Nottwil, LU, Switzerland, 6207
- Schweizer Paraplegikerzentrum
-
-
SG
-
Valens, SG, Switzerland, 7317
- Rehaklinik
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients with a sustained pain sensation in the bladder (for the first five patients).
Patients staying as inpatients with long-term (> 2 weeks) urethral or suprapubic catheters.
- Age > 18 years
- Ability to read, write and speak German or French
- Women of child bearing potential must test negative on standard urine pregnancy test two weeks prior to the start of the study and must agree to practice appropriate contraceptive methods until the end of the study (e.g. oral contraceptive, IUD, intra-muscular contraceptive, abstinence).
- Provision of voluntary consent to participate in the study, following a full explanation of the nature and purpose of the study, by signing the informed consent approved by the cantonal Ethics Committee (IEC) prior to all evaluations
Exclusion Criteria:
- Symptomatic UTI
- Hematuria
- Fever (tympanic temperature > 38.5°C)
- Surgical intervention to genito-urinary tract in the last 6 months
- Patients receiving any other concurrent catheter irrigation
- Known allergy or sensitivity to any of the ingredients in Uro-Tainer® Polihexanide 0.02%
- Known allergy or sensitivity to chlorhexidine
- Pregnancy or Lactation
- Simultaneous participation in another interventional trial
- Administration of any other catheter irrigation 1 week prior to study
- Administration of any of the following medications 4 weeks prior to study entry, unless they have been used at a stable regimen : antibiotics, antipyretics, antihistamines, medications susceptible to cause an autonomic response or to mask an allergic reaction.
- For the first five patients: impaired pain sensation in the bladder for the first five patients: Administration of any antipyretics and analgesic.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Long-term catherized patients
Uro-Tainer Polihexanide 0.02% 100ml rinsing solution
|
Catheters will be rinsed by gravity feed with 100ml solution of UT-P 0.02% once a day for a maximum of 5 instillations.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
to assess the tolerability of Uro-Tainer® Polihexanide 0.02%
Time Frame: Day 1, Day 2, Day 3, Day 4, Day 5
|
Change in Visual Analogue Scale (VAS) Score for patients with sustained pain sensation in the bladder Bladder spasms Blood pressure (change in SBP ≥ 40 mmHg is a discontinuation criterion, see 7.4.3)
Heart rate Change in tympanic temperature Urine Dipstick (LEU) Occurrence of Flushing Occurrence of Sweating
|
Day 1, Day 2, Day 3, Day 4, Day 5
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
To assess the safety of Uro-Tainer® Polihexanide 0.02% in long-term catheterized patients
Time Frame: Day 1, Day 2, Day 3, Day 4, Day 5
|
Adverse Events
|
Day 1, Day 2, Day 3, Day 4, Day 5
|
Collaborators and Investigators
Investigators
- Principal Investigator: Jürgen Pannek, Prof., Schweizer Paraplegikerzentrum Nottwil
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- OPM-G-H-1101
- Cl V-1 3-03-010344 (Other Identifier: EUDAMED)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Complications; Catheter, Urinary (Indwelling Catheter) (Suprapubic)
-
TriHealth Inc.TerminatedObstruction; Catheter, Infusion Catheter (Vascular) | Catheter; Complications (Indwelling Catheter)United States
-
TriHealth Inc.CompletedObstruction; Catheter, Infusion Catheter (Vascular) | Catheter; Complications (Indwelling Catheter)United States
-
West China HospitalCompleted
-
Bulent Ecevit UniversityCompleted
-
University of SouthamptonBlueWind Medical; University Hospital Southampton NHS Foundation Trust; National...WithdrawnIndwelling Urinary Catheter UsersUnited Kingdom
-
William Beaumont HospitalsTerminatedUrinary Tract Infections | Catheter Infection | Catheter-Related Infections | Catheter; Infection (Indwelling Catheter) | Catheter BacteraemiaUnited States
-
Linkoeping UniversityCompletedCatheter-Related Infections | Catheters, IndwellingSweden
-
Damanhour Teaching HospitalRecruitingCatheter Complications | Catheter Blockage | Catheter Dysfunction | Epidural; Anesthesia | Catheter BreakageEgypt
-
Montefiore Medical CenterCompletedInfection Due to Indwelling Urinary CatheterUnited States
-
Gülçin Özalp GerçekerCompletedCatheter Complications | Catheter LeakageTurkey
Clinical Trials on Uro-Tainer Polihexanide 0.02%
-
SIFI SpACompletedAcanthamoeba KeratitisItaly, United Kingdom, Poland